Testosterone undecanoate (Aveed/Nebido) is a long-acting testosterone ester injected every 10 weeks. Cypionate is the short-acting standard most US TRT clinics use, injected weekly or twice-weekly. For almost every American TRT patient, cypionate wins — because Aveed requires in-clinic administration under an FDA REMS program, and the 10-week curve is harder to fine-tune than it looks.
That answer is the opposite of what most clinic landing pages will tell you. This guide explains why, breaks down the pharmacology, and shows you what the real choice looks like in 2026.
What is testosterone undecanoate, and how is it different from cypionate?
Testosterone undecanoate is testosterone attached to an 11-carbon undecanoic acid ester — a long fatty-acid chain that slows absorption from the injection site, stretching the active half-life to roughly 33 days. Cypionate uses an 8-carbon ester with a half-life closer to 8 days. Same molecule, different release speed.
Both products are real testosterone after the body's esterases cleave the side chain. The difference is purely how fast that release happens. Undecanoate's longer chain creates a slower drip from the muscle depot, which is why you can dose it every 10 weeks instead of every 7 days.
There's another important distinction: the carrier oil. US-marketed Aveed is suspended in castor oil with benzyl benzoate as a co-solvent. Cypionate sold in the US uses cottonseed oil. That castor-oil base is part of what makes undecanoate higher-viscosity and harder to inject — it's why the dose is 3 mL of oil per shot instead of the 0.5-1 mL most cypionate users push weekly.
Did You Know? Aveed is the only FDA-approved long-acting injectable testosterone in the United States. Nebido — same molecule, same dose schedule — has been sold in Europe, the UK, Canada, Australia, and most of the world since 2003. Aveed didn't get FDA approval until 2014, eleven years later, and the delay came down to safety concerns about pulmonary oil microembolism.
For the full picture on cypionate's half-life and dosing math, see our testosterone cypionate half-life breakdown.
Is testosterone undecanoate better than cypionate for TRT?
For the vast majority of US TRT patients, no — cypionate is the better choice. The 10-week dosing interval sounds convenient until you account for the FDA REMS (Risk Evaluation and Mitigation Strategy) requirement, which forces every Aveed injection to happen in a certified clinic with a 30-minute post-shot observation period. That single rule kills most of the "convenience" argument.
There are narrow situations where undecanoate genuinely makes sense:
- You travel internationally for work and cannot reliably maintain a weekly injection schedule
- You have a strong needle aversion and the trade-off (six shots per year vs 52) is worth driving to a clinic
- You're already in a healthcare setting routinely for another reason
- You live outside the US, where Nebido can be administered in primary care without REMS overhead
For everyone else — the average 35-50 year old man self-injecting at home — cypionate offers tighter dose control, lower per-month cost, and no clinic visits. The 8-day half-life means you can correct mistakes (or symptoms) within two weeks. With undecanoate, a dose that's even slightly off is something you live with for 10 weeks.
Our enanthate vs cypionate comparison goes deeper on why shorter esters dominate US prescribing.
What's the difference between Aveed and Nebido?
Aveed and Nebido are the same molecule — testosterone undecanoate at 250 mg/mL in castor oil — sold under different brand names in different markets. Aveed is the US brand, manufactured by Endo Pharmaceuticals. Nebido is the international brand from Bayer, available in over 90 countries since 2003. Pharmacologically identical. Regulatorily, world apart.
The differences come down to access:
| Factor | Aveed (US) | Nebido (International) |
|---|---|---|
| Manufacturer | Endo Pharmaceuticals | Bayer AG |
| Dose | 750 mg in 3 mL | 1000 mg in 4 mL |
| Loading schedule | Week 0, then week 4, then every 10 weeks | Week 0, then week 6, then every 10-14 weeks |
| Self-injection allowed | No (REMS program) | Yes, in many countries |
| Required observation | 30 minutes post-injection | None in most markets |
| Typical cost (US) | $1,500-2,500 per shot retail | N/A (not sold in US) |
If you're a US patient reading European or Australian forums about Nebido — those guys self-inject at home, often in primary care, with no observation requirement. That experience does not translate to Aveed. Same drug, different rulebook.
How does the 10-week dosing schedule actually work?
Aveed and Nebido start with a loading phase to reach steady state, then move to a maintenance interval. The standard US Aveed protocol is: injection at week 0, second injection at week 4, then every 10 weeks indefinitely. That gives you roughly six injections per year after the loading phase, or seven during your first year.
The loading shot exists because a 33-day half-life means you need multiple half-lives to reach steady state. One shot only fills the depot partway. Without the week-4 booster, you'd spend the first 16-20 weeks ramping up to therapeutic levels — exactly the kind of slow start that erodes patient compliance.
After loading, the dosing window has some flexibility. The Aveed prescribing information allows the maintenance interval to flex between 10 and 14 weeks based on serum testosterone trough levels. International Nebido protocols often run 10-14 week intervals from the start, individualized per patient.
The clinical reality: most men land in the 10-11 week window. Stretching to 14 weeks usually produces noticeable symptom return — fatigue, libido drop, mood shift — by week 12. The "10-week shot" marketing is closer to truth than the "every 14 weeks if you want" flexibility the label allows.
What does the testosterone undecanoate peak-trough curve look like?
Undecanoate's "stable levels" reputation comes from comparing it to monthly testosterone enanthate or cypionate depots from the 1970s, not modern weekly cypionate protocols. With a 33-day half-life, every Aveed shot produces a supraphysiologic peak roughly 7 days after injection, followed by a long glide down across weeks 4-10.
Here's the typical pattern across one 10-week interval:
- Day 0: Injection. Levels begin climbing.
- Day 7-10: Peak. Total testosterone often reaches 900-1,300 ng/dL.
- Day 14-21: First plateau. Levels stay near peak.
- Week 4-6: Mid-cycle. Levels glide down through 700-900 ng/dL.
- Week 8-10: Trough. Total testosterone typically lands 350-500 ng/dL — sometimes lower.
- Week 10: Next injection. Cycle restarts.
That curve has two practical consequences. First, the early-cycle peak is high enough to trigger estradiol conversion in many men — water retention, mood swings, and occasional nipple sensitivity in weeks 1-3 are common. Second, the week 8-10 trough often pulls total testosterone back into the symptomatic range. Men report energy and libido dropping noticeably in the last two weeks before the next shot.
By contrast, twice-weekly cypionate keeps the peak-trough swing under 30% in most protocols. That's why our injection timing guide leans hard on more frequent dosing — the variance, not the average, is what most men feel.
For more on how the peak-trough experience actually translates to daily symptoms, see our breakdown on how long a testosterone injection really lasts.
Why can't you self-inject Aveed in the US?
Aveed carries an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) because of two rare but serious risks: pulmonary oil microembolism (POME) and anaphylaxis. POME happens when castor-oil droplets enter pulmonary circulation, causing acute respiratory distress within minutes of injection. Anaphylaxis is a separate allergic reaction. Both have been reported in post-marketing surveillance of Nebido and during Aveed's clinical trials.
The REMS rules every Aveed clinic must follow:
- Certified provider only. The injector must be enrolled in the Aveed REMS program.
- 30-minute observation period. Every patient stays in clinic for 30 minutes after every injection — not just the first one.
- Resuscitation equipment on-site. The clinic must have epinephrine, oxygen, and emergency airway management ready.
- No prescriptions to patient. The drug cannot be dispensed to the patient to self-inject at home, period.
According to the FDA's Aveed prescribing label, the POME risk is small in absolute terms but clinically serious — symptoms include cough, dyspnea, chest tightness, and syncope, typically within seconds to minutes of the injection finishing.(1) The 30-minute window catches essentially all observed POME events. Self-injection at home would defeat the entire safety architecture.
This is the single biggest reason undecanoate hasn't displaced cypionate in US TRT. A weekly cypionate patient does the shot in 90 seconds at home with a 25-gauge insulin needle. An Aveed patient drives to a clinic, gets a 3 mL intramuscular shot from a registered nurse, sits in the waiting room for 30 minutes, drives home. Six times a year, every year. The math on time alone — never mind copays — favors cypionate decisively for most men.
Undecanoate is also intramuscular-only by route, full stop. Cypionate has expanded into subcutaneous administration in recent years; see our subcutaneous vs intramuscular comparison for the trade-offs.
How do undecanoate and cypionate compare on cost, convenience, and side effects?
Cypionate wins on cost (roughly $30-80/month retail vs $1,500-2,500 per Aveed shot), convenience (52 home injections beat 6-7 in-clinic visits with mandatory 30-minute observation), and peak-trough stability (~25-35% twice-weekly swing vs ~60-70% on undecanoate). The two side-effect profiles are comparable except for pulmonary oil microembolism (POME), which only exists with undecanoate.
Here's the side-by-side that most clinic pages don't put on a single line:
| Factor | Testosterone Undecanoate (Aveed) | Testosterone Cypionate |
|---|---|---|
| Half-life | ~33 days | ~8 days |
| Dosing interval | Every 10 weeks (after loading) | Weekly or twice-weekly |
| Loading required | Yes (week 0, week 4) | No |
| Self-injection in US | Not allowed (REMS) | Standard |
| Route | IM only | IM or subQ |
| Carrier oil | Castor oil | Cottonseed oil |
| Typical dose | 750 mg per shot | 100-200 mg per week |
| Peak-trough fluctuation | High (~60-70%) | Low (~25-35% twice-weekly) |
| Estradiol pattern | Spike at week 1-3, drift down | Stable with twice-weekly |
| Hematocrit risk | Comparable to cypionate | Comparable |
| POME risk | Yes (rare but real) | No |
| Anaphylaxis risk | Boxed-warning level | Standard injectable allergy risk |
| Typical US cost (retail) | $1,500-2,500 per shot | $30-80 per month |
| Typical US cost (insured copay) | $0-150 per shot if covered | $5-30 per month |
| Office visits per year | 6-7 | 1-2 (annual labs) |
Three things stand out. First, the cost gap is enormous unless insurance is covering Aveed in full — and many insurers tier Aveed as specialty pharmacy with prior authorization. Second, the peak-trough swing on undecanoate is roughly double what twice-weekly cypionate produces. Third, every other side effect risk is comparable except POME, which only exists with undecanoate.
The convenience argument breaks down once you count clinic visits. Six 30-minute observation appointments per year is roughly 3 hours plus travel. Most weekly self-injectors spend less than that across a full year.
Is oral testosterone undecanoate (Jatenzo, Tlando) the same thing?
No — oral undecanoate is a separate product category with completely different pharmacokinetics. Jatenzo (testosterone undecanoate capsules, Clarus Therapeutics) and Tlando (Antares Pharma) are twice-daily oral softgels that bypass the liver via the lymphatic system. Same molecule as injectable undecanoate, but the oral route changes everything about how it behaves in the body.
Key differences:
- Frequency: Oral undecanoate is dosed every 12 hours, every day. Injectable undecanoate is every 10 weeks.
- Peak timing: Oral peaks 4-6 hours after each dose; injectable peaks 7-10 days after each shot.
- Half-life: Oral has a functional half-life of about 6-9 hours (which is why it's twice-daily). Injectable is 33 days.
- Food requirement: Oral must be taken with food (lipid content drives lymphatic absorption). Injectable doesn't care what you ate.
- Liver impact: Oral bypasses first-pass hepatic metabolism via the lymphatic route, which is the only reason it's FDA-approved (older oral testosterone caused hepatotoxicity).(2)
If a clinic is "switching you to undecanoate," ask which form. The injectable and the oral product are clinically unrelated in everything except the molecule's name. Oral undecanoate has its own narrow niche — men with extreme needle aversion or specific contraindications to injection — but it carries blood pressure warnings and costs $300-500/month even with insurance.
For another oral-alternative route, see our testosterone gel breakdown.
When should you do bloodwork on testosterone undecanoate?
The trough-draw rule for a 10-week ester is completely different from cypionate. For Aveed or Nebido, draw blood at week 9 or 10 — immediately before your next scheduled injection, when serum testosterone is at its lowest point. The week-9 trough is the number your clinician should be titrating against. A peak-day draw at week 1 will read 900-1,300 ng/dL on almost any patient and tells you nothing useful.
Cypionate trough is much simpler: draw the morning of injection day, before that week's shot. The peak-trough swing is so much smaller that even mid-week draws give workable data.
Recommended undecanoate bloodwork rhythm:
- Baseline: Before the first injection — total testosterone, free testosterone, estradiol (sensitive assay), CBC for hematocrit, lipid panel, PSA.
- Mid-cycle check: Week 4-5 of your first 10-week maintenance cycle. Use this to confirm you've hit the expected peak-decline curve.
- Trough draw: Day of injection at week 10. This is your steady-state floor.
- Routine cadence: Every 6 months after stable trough labs, repeat the full panel before the scheduled injection.
The Endocrine Society's clinical practice guideline on testosterone therapy recommends trough-targeted titration for all long-acting injectables specifically because peak-day measurements overestimate steady-state exposure.(3) For undecanoate, that means scheduling labs on injection day, not the convenient appointment two weeks later.
Can you switch from cypionate to undecanoate (or back)?
Yes, switching between cypionate and undecanoate is clinically routine — the testosterone molecule is identical, only the release ester differs. The transition window matters: switch timing affects how smoothly your levels bridge between the two protocols.
Cypionate to undecanoate. Take your last cypionate dose, wait 7 days, get the first Aveed loading shot. The cypionate depot is functionally cleared by day 21, and your week-4 Aveed booster will have you at steady state by week 6-8.
Undecanoate to cypionate. Wait until you're at the natural trough — week 10, immediately before the missed next shot. Start cypionate on what would have been your next Aveed day. There's no residual depot worth bridging; the undecanoate is essentially gone by week 12.
In both directions, the symptom transition is the part to watch, not the chemistry. A cypionate patient moving to undecanoate often reports a "honeymoon" through weeks 1-4 (peak coverage), then symptom return at weeks 8-10 (deep trough). The reverse direction often feels stable but loses the once-every-10-weeks freedom that motivated the original switch.
If you're considering the move, log symptoms every other day across one full cycle in either direction. Our protocol tracking guide covers the variables worth recording.
How Himcules Helps You Track an Undecanoate or Cypionate Protocol
Whether you're on weekly cypionate or 10-week Aveed, the same tracking principle applies: a structured log of shot date plus daily energy, libido, and mood ratings is the only way to know whether your protocol is actually working. With cypionate the data accumulates fast — 52 injections per year means 52 data points minimum. With undecanoate the stakes per data point are higher — only six shots per year, and each trough is 10 weeks away.
Himcules gives you two features that matter specifically for long-ester protocols: timeline charts that overlay your symptom ratings against time-since-injection (so the week-8-to-10 trough drop becomes visible at a glance) and shot logging that timestamps every injection to the minute. For undecanoate patients, the trough-detection chart is the single most valuable view. For cypionate patients, the injection-rotation log keeps site-fatigue and lump formation from sneaking up.
You can download Himcules free on iOS to track your shot dates, log daily symptoms across a full ester cycle, and spot trough drops before they ambush you.
Key Takeaways
Q: Is undecanoate better than cypionate? A: Not for most US TRT patients. Aveed's FDA REMS forces every shot to happen in-clinic with a 30-minute observation window, which erases most of the convenience benefit. Cypionate gives tighter dose control and far lower cost.
Q: What is the strongest form of testosterone? A: All injectable testosterone is the same molecule — the ester only changes the release speed. Undecanoate stays active longest (33-day half-life), cypionate is shorter (8 days), but neither is intrinsically "stronger" once levels stabilize.
Q: Is testosterone undecanoate good for TRT? A: It works pharmacologically, but it's a poor practical fit for most US men. The 10-week interval sounds convenient until you factor in REMS clinic visits and the high peak-trough swing. Internationally (Nebido), where self-injection is allowed, it's more competitive.
Q: What is AVEED used for? A: Aveed is the US-approved long-acting injectable testosterone for adult men with primary hypogonadism or hypogonadotropic hypogonadism — the same indication as cypionate. It's dosed every 10 weeks after a loading phase.
Q: Is AVEED available in the US? A: Yes, but only under the FDA REMS program. You can't self-inject it at home; every dose must be administered by a certified provider with a 30-minute post-shot observation period.
Q: Is Aveed the same as Nebido? A: Same molecule (testosterone undecanoate), same 250 mg/mL concentration, same castor-oil base. Different brand names — Aveed is the US version from Endo, Nebido is the international version from Bayer. The big difference is regulatory: Nebido allows self-injection in most countries, Aveed does not in the US.
Q: How long does testosterone undecanoate stay in your system? A: The active half-life is roughly 33 days, so a single shot remains pharmacologically active for about 10-12 weeks before levels return to baseline. Detectable trace amounts can persist beyond that.
Sources
- U.S. Food and Drug Administration, "AVEED (testosterone undecanoate) Injection Prescribing Information," 2014
- Swerdloff RS et al., "A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men," The Journal of Clinical Endocrinology & Metabolism, 2020
- Bhasin S et al., "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline," J Clin Endocrinol Metab, 2018
- Mulhall JP et al., "Evaluation and Management of Testosterone Deficiency: AUA Guideline," American Urological Association, 2018
- Behre HM et al., "Long-term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, 1999
- Schubert M et al., "Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation During Long-Term Treatment of Men with Hypogonadism," J Clin Endocrinol Metab, 2004
- Middleton T et al., "Complications of Injectable Testosterone Undecanoate in Routine Clinical Practice," European Journal of Endocrinology, 2015
- Morgentaler A et al., "Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions," Mayo Clinic Proceedings, 2016
This article is for informational purposes only and is not medical advice. Always consult your healthcare provider about your TRT protocol.